Compare Dow Jones Industrial Average ETF (DIA) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Jones Industrial Average ETF vs BIO-TECHNE Corp — how do they compare? Dow Jones Industrial Average ETF trades at $525.78, while BIO-TECHNE Corp trades at $71.23 (market cap $11.10B). The key difference: BIO-TECHNE Corp pays a 0.45% dividend while Dow Jones Industrial Average ETF pays none. Which is the better fit depends on your goals.
| DIA | TECH | |
|---|---|---|
52-Week High | $530.02 | $71.38 |
52-Week Low | $435.72 | $43.31 |
Market Cap | — | $11.10B |
Sector | — | Health |
Enterprise Value | — | $11.18B |
Dividend Yield | — | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DIA trades at $524.40, down 0.27% on the day, with a bullish technical signal from moving averages and neutral oscillators. The ETF tracks the Dow Jones Industrial Average, offering exposure to 30 large-cap U.S. stocks. Recent news highlights its 52-week high achievement and inclusion of Alphabet, boosting tech exposure. Dividend distributions are scheduled through mid-2026, providing income alongside capital appreciation potential.
Outlook remains positive given strong institutional backing and historical performance, but risks include market volatility and Federal Reserve policy shifts. The ETF suits investors seeking diversified blue-chip exposure with moderate growth and income, though concentration in a few stocks may amplify sector-specific downturns.
Bio-Techne (TECH) trades at $71.36, showing minimal daily movement (+0.08%) as the market digests Merck KGaA's $73 per share acquisition offer. The stock sits just 2.3% below the buyout price, with technical indicators showing bullish momentum. Fundamentally, the company maintains strong gross margins (64.96%) but faces declining net income margins (6.01% in 2025). Recent earnings show mixed results with one beat and two misses in the last four quarters.
The acquisition premium provides near-term upside potential, though shareholder litigation risks exist regarding deal fairness. Long-term investors face uncertainty about post-acquisition prospects, while current valuation metrics (P/E 101.94) appear stretched without the takeover scenario. The $73 offer price represents the primary catalyst, with downside risk to $50 if the deal fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Dow Jones Industrial Average ETF
The ETF is designed to track the performance of the securities and the stocks in the Dow Jones Industrial Average Index. To maintain the composition and weightings, the advisor adjusts the ETF from time to time to conform to periodic changes in the index target.
Read more on DIA →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
